Love of Science, CSUSM Fuels Alumnus at Local Biotech

Five years ago, when Christopher Greely first acquired a leadership position at the San Diego biotech where he works and was charged with expanding his team by almost tenfold, he knew just the profile he was looking for.

Scientists who had the proper academic underpinning. Scientists who were passionate and driven. Scientists who weren’t afraid to roll up their sleeves and work hard.

And it certainly didn’t hurt if they were, like him, scientists who had graduated from Cal State San Marcos.

“I brought on board some of my previous classmates and really kept an eye out for any fresh grads from CSUSM who were just looking for an opportunity,” Greely said. “Because I know the educational basis that they're operating with and their scientific expertise. But on top of that, one of the things that I've noticed about the CSUSM community is really the push to strive for more.”

Greely would know, since he is one of those strivers. One of two children of a single mother who was a victim of domestic abuse, the North County native embarked on a decade-long journey (interrupted multiple times at multiple schools) in higher education that ended in a single academic year at CSUSM, from which he graduated with a degree in biology in 2017.

What a year it was, however. It helped propel Greely into a job at Carlsbad’s Trinity Biotech, which he then parlayed into a position at TriLink BioTechnologies by May 2018. Almost seven years later, he’s still there, having been promoted six times, most recently in 2023 to associate director of nucleic acid products manufacturing.

TriLink has about 200 employees, and Greely estimates that up to 10% of them are CSUSM alumni. Included in that group are a couple of others who are high in the company’s hierarchy: Justin Barbosa, vice president and general manager of discovery; and Evan Myers, associate director of process development.

“CSUSM provides a high-level education that prepares us for the future,” said Myers, a 2016 graduate who tutored Greely through the STEM Success Center when they were both students and now works with him closely at TriLink. “Chris is an exceptional worker who brings huge value to the company.”

At no time was that more clear than in the early stages of the COVID-19 pandemic. While the virus was beginning to rage out of control, BioNTech, the German biopharma giant and an existing client of TriLink’s, approached the company asking for its assistance in producing a vaccine that would combat COVID.

TriLink, which specializes in the synthesis of nucleic acids and mRNA capping analogs, possesses a proprietary technology called CleanCap that simplifies mRNA manufacturing by removing additional enzymatic steps, resulting in higher efficiency and better yields. BioNTech wanted as much CleanCap as it could get its hands on.

There was just one problem: TriLink had recently moved into a new building in Sorrento Valley, and its GMP (an industry term that stands for “good manufacturing practices”) lab wasn’t operational yet. So while Greely was building out his team from five people to 45 to prepare for the heightened demand from BioNTech, he also had to devise a solution that would bridge the gap from where TriLink was in its manufacturing capacity to where it was going. That involved doing some of their work in a standard chemistry lab like the ones Greely utilized back at CSUSM and the rest in a temporary GMP lab.

“It enabled us to partner with BioNTech and Pfizer and say, ‘Hey, we understand we’re not equipped right now to satisfy your needs, but we’ll make it happen,’ ” Greely said.

By the time the state-of-the-art lab facility was completed, Greely and his team were ready to hit the ground running. Starting on Valentine’s Day in 2021, they worked around the clock every day for about eight months to ensure that BioNTech had enough CleanCap to produce the vast amounts of COVID vaccine necessary to inoculate millions of people around the globe.

“It was an enormous satisfaction knowing that you were helping your community, the overall population, the whole world,” Greely said. “During the pandemic, some of my lead engineers would say things like, ‘I’m coming in at 2 a.m. because you called me, because the equipment is down, and at the end of the day, I want my daughter to be able to go back to school.’ That was huge.”

Greely was prepared for such a period of growth, both personal and professional, because of the training he received at CSUSM. He vividly remembers a biochemistry course with professor Kambiz Hamadani that was three units but seemed like twice that. At the time, Greely felt overwhelmed by the volume of work, but once he was a new employee at TriLink, he suddenly found himself grateful for the grueling experience.

“The principles that Hamadani taught and the ground that his virtual lab covered prepared me for some of the standard operating procedures I would see in the lab within my first three months of starting my job,” he said. “That was eye-opening for me, the real-world application of what’s being taught at CSUSM.”

After growing like gangbusters during the pandemic, TriLink contracted in 2023 as the demand for the COVID vaccine decreased. But the company is coming off a prosperous year fueled by the development of a new iteration of CleanCap that’s being used by industry partners for cell and gene therapy that could help cure diseases.

“Whenever I interview anyone, they always ask me, ‘What do you love about TriLink?’ ” Greely said. “And my response always stays the same: I am never bored. It’s all about pushing to that new benchmark, clearing that next hurdle, seeing how far we can take our intellectual property for the betterment of the human experience.”

Media Contact

Brian Hiro, Communications Specialist

bhiro@csusm.edu | Office: 760-750-7306